|
Vaso's Revenue per Employee
Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales
With a revenue increase of 39.45% in the forth quarter 2024, year on year to cumulative value of $87 million, Vaso's revenue per employee grew on a trailing twelve months basis to $ 2,798,935, this is below the company average. Within the Healthcare sector Employees of 23 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 290, from total ranking in previous quarter at 302. Vaso has 31 employees.
What is Sales per Employee Ratio?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| VASO Revenue per Employee |
(Dec 31 2024)
IV. Quarter |
(Sep 30 2024)
III. Quarter |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Sep 30 2023)
III. Quarter |
| Y / Y Revenue Change |
39.45 % |
1.56 % |
4.84 % |
-20.17 % |
-2.92 % |
| Sales per Employee (TTM) $ |
2,798,935 |
2,551,419 |
2,541,129 |
2,511,129 |
2,663,806 |
| VASO's Total
Ranking |
# 290 |
# 302 |
# 0 |
# 0 |
# |
| Seq. Revenue Change |
30.67 % |
3 % |
7.54 % |
-3.66 % |
-4.83 % |
| Revenue per Employee Statistics |
| High |
Average |
Low |
| $ 3,470,680 |
$ 2,939,255 |
$ 1,531,800 |
| (Dec 31 2024) |
|
(June 30. 2015) |
Date modified: 2025-04-02T04:00:00+00:00
| Companies with similar Revenue per Employee for 12 months ending Dec 31 2024, within Healthcare Sector | Revenue per Employee | Revenue 12 months ending Dec 31 2024 | Number of Employees Dec 31 2024 | | Catalyst Pharmaceuticals Inc | 4,639,000.00 | $ 491.734 Million | 106 | | Esperion Therapeutics Inc | 4,615,472.22 | $ 332.314 Million | 72 | | Aytu Biopharma Inc | 4,273,125.00 | $ 68.370 Million | 16 | | Geron Corp | 4,249,722.22 | $ 76.495 Million | 18 | | Protagonist Therapeutics inc | 3,878,866.07 | $ 434.433 Million | 112 | | Exelixis Inc | 3,831,627.21 | $ 2,168.701 Million | 566 | | Mirum Pharmaceuticals Inc | 3,743,200.00 | $ 336.888 Million | 90 | | Hims and Hers Health Inc | 3,708,881.91 | $ 1,476.135 Million | 398 | | Intra cellular Therapies Inc | 3,370,554.46 | $ 680.852 Million | 202 | | Adapthealth Corp | 3,209,621.06 | $ 3,260.975 Million | 1,016 | | Xeris Biopharma Holdings Inc | 3,124,153.85 | $ 203.070 Million | 65 | | Siga Technologies Inc | 3,015,638.04 | $ 138.719 Million | 46 | | Journey Medical Corp | 2,954,421.05 | $ 56.134 Million | 19 | | Trisalus Life Sciences Inc | 2,932,800.00 | $ 29.328 Million | 10 | | Harmony Biosciences Holdings inc | 2,902,109.76 | $ 713.919 Million | 246 | | Evolus Inc | 2,861,330.77 | $ 371.973 Million | 130 | | Entrada Therapeutics Inc | 2,810,426.67 | $ 210.782 Million | 75 | | Vaso Corporation | 2,798,935.48 | $ 86.767 Million | 31 | | Tg Therapeutics Inc | 2,492,454.55 | $ 329.004 Million | 132 | | United Therapeutics Corporation | 2,463,527.40 | $ 2,877.400 Million | 1,168 | | Biocryst Pharmaceuticals Inc | 2,287,878.17 | $ 450.712 Million | 197 | | Transmedics Group Inc | 2,275,979.38 | $ 441.540 Million | 194 | | Inspire Medical Systems inc | 2,271,439.09 | $ 801.818 Million | 353 | | Xoma Royalty Corporation | 2,191,307.69 | $ 28.487 Million | 13 | | Arcutis Biotherapeutics Inc | 2,136,326.09 | $ 196.542 Million | 92 | | Sunshine Biopharma Inc | 2,051,428.41 | $ 34.874 Million | 17 | | Vertex Pharmaceuticals Inc | 2,040,759.26 | $ 11,020.100 Million | 5,400 | | Castle Biosciences Inc | 2,024,810.98 | $ 332.069 Million | 164 | | Capricor Therapeutics inc | 2,024,587.73 | $ 22.270 Million | 11 | | Krystal Biotech Inc | 2,003,551.72 | $ 290.515 Million | 145 |
|
